Kura Oncology Reports First Quarter 2018 Financial Results and Provides Corporate Update
May 08, 2018 16:05 ET
|
Kura Oncology, Inc.
– Registration-directed trial of tipifarnib in HRAS mutant head and neck squamous cell carcinomas (HNSCC) on track to initiate in second half of 2018 – – Data from multiple Phase 2 trials of...
Kura Oncology to Present at Deutsche Bank 43rd Annual Health Care Conference
May 03, 2018 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, May 03, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Announces New Patent for Tipifarnib in Hematologic Malignancies
May 02, 2018 07:30 ET
|
Kura Oncology, Inc.
– Newly issued patent expands protection for tipifarnib in U.S., provides exclusivity in certain CXCL12-expressing cancers to 2037 – – Second U.S. patent for tipifarnib reinforces potential for...
Kura Oncology to Report First Quarter 2018 Financial Results
May 01, 2018 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, May 01, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Announces Upcoming Presentations at AACR Annual Meeting 2018
April 09, 2018 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, April 09, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Provides Regulatory Update on Tipifarnib and Reports Fourth Quarter and Full Year 2017 Financial Results
March 12, 2018 16:05 ET
|
Kura Oncology, Inc.
– Company plans to initiate registration-directed trial of tipifarnib in second half of 2018 following recent end of Phase 2 meeting with the FDA – – Single-arm trial to enroll at least 59...
Kura Oncology to Present at Cowen and Company 38th Annual Health Care Conference
March 06, 2018 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, March 06, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology to Report Fourth Quarter and Full Year 2017 Financial Results
March 05, 2018 16:05 ET
|
Kura Oncology, Inc.
SAN DIEGO, March 05, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Provides Update on Phase 2 Trial of Tipifarnib in HRAS Mutant Head and Neck Cancer
February 15, 2018 11:00 ET
|
Kura Oncology, Inc.
– Confirmed partial responses observed in five of six evaluable patients with HRAS mutant HNSCC – – Rate of enrollment increasing with three additional patients enrolled in four months – –...
Kura Oncology to Present at the Leerink Partners 7th Annual Global Healthcare Conference
February 08, 2018 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Feb. 08, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...